Aurobindo Pharma Acquisition Worth ₹146.4 Cr

Aurobindo Pharma Board Meeting Date

Aurobindo Pharma's board meets 4 November 2026 to consider Q2 and half-year results and a possible interim dividend. Trading window stays closed until 6 November.

Aurobindo Pharma Other Announcement

Aurobindo Pharma Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as mandated by SEBI regulations.

Aurobindo Pharma Business Update

Aurobindo Pharma received USFDA final approval for Perampanel Tablets in multiple strengths. The product will be manufactured by its subsidiary and launched in Q3FY27.

Aurobindo Pharma Acquisition

Aurobindo Pharma's subsidiary, Apitoria Pharma, has completed the acquisition of the Contract Research Services business of A1 Biochem Group. The deal integrates CRO capabilities into Apitoria's operations.

Aurobindo Pharma Merger & Restructuring Worth ₹33.8 Cr

Aurobindo Pharma's subsidiary, Apitoria Pharma, completed a 20% stake dilution in A1 Biochem Labs. Dr. Rajendra Gadikota subscribed to securities worth ₹33.80 Crore.

Value

₹33.80 Cr

Aurobindo Pharma Product Launch

Acrotech Biopharma launched ADQUEY (difamilast 1% ointment) in the U.S. and established a dedicated dermatology business unit to support this market entry.

Emkay Global Financial Services Acquisition Worth ₹21.38 Cr

Emkay Capital, a subsidiary, will acquire Emkay Investment Managers for Rs.21.38 Crore cash. The related-party deal is at arm's length and payable in tranches.

Value

₹21.38 Cr

Execution

90 days

TVS Motor Company Acquisition Worth ₹25,000 Cr

TVS Motor will acquire 100% of Harita ARC Limited, a related-party shell, for a stated Rs 25,000 Crore. It supports the proposed consumer finance demerger.

Value

₹25,000 Cr

Rite Zone Chemcon India Acquisition Worth ₹4.97 Cr

Rite Zone Chemcon's board approved acquiring 51% of Cleanux Green Solution via share swap for about INR 4.97 Crore. The board also approved preferential issues and an EGM on 23 November 2026.

Value

₹4.97 Cr

eClerx Services Acquisition Worth ₹15.57 Cr

eClerx's board approved buying about 2% of Personiv Eclipse Inc. from its wholly owned subsidiary eClerx LLC for USD 1.64 million. The intra-group transfer adds no change to aggregate ownership.

Value

₹15.57 Cr

Execution

1 Month

Fortis Healthcare Acquisition Worth ₹277 Cr

Fortis Healthcare's wholly-owned subsidiary IHL acquired Suguna Hospital's business and land in Bengaluru via slump sale. The cumulative consideration is approximately INR 277 Crore, consummated today.

Value

₹277.0 Cr

Authum Investment & Infrastructure Acquisition

NCLT approved the consortium resolution plan for A A Estates Private Limited, with Authum as a resolution applicant. No consideration amount is disclosed.